News | November 10, 2025
AstraZeneca delivers double-digit growth
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies now has 29 active product approvals in Vietnam alone
Poviztra is a second brand of Wegovy
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
Subscribe To Our Newsletter & Stay Updated
